[Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen].

Mengqiu Gao; Jianen Gao; X G; Wei Shu; Juan Du; Ruiming Liang; Guihui Wu; Yonggang Pei; Yan Xia; Qian Cai; K Y Lyu; Chen Cai; Y Q Wu; X.-J. Li; Qinqin Liu; Liang Jin; Qing Wu; Yu Xiong; M W Li; Yuqi Zhou; H B Kuang; X F Wang; Fei Ren; X H Chen; Shujun Geng; Yong Zhou; Wei Sha; G L Yang; Hua Wang; Yuan Zhan; Y H Liu; Lin Li

doi:10.3760/cma.j.cn112147-20240229-00117

Abstract

To explore the characteristics of adverse drug reactions during the 24-week therapy with delamanid-containing regimen for patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis (MDR/RR-PTB).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gao et al. (2024) studied this question.

synapsesocial.com/papers/68e60873b6db64358759ba90 https://doi.org/10.3760/cma.j.cn112147-20240229-00117

View at Publisher

Ask AI

Bookmark

Share

[Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen].

Abstract

Discussion

Cite This Study

[Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen].

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers